Amarin to have strong execution year ahead, says Piper Sandler per thefllyonthewall.com (Overweight | AMRN Message Board Posts

Amarin Corporation plc

  AMRN website

AMRN   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  8240 of 8383  at  2/26/2021 7:58:20 AM  by

JBWIN


Amarin to have strong execution year ahead, says Piper Sandler per thefllyonthewall.com (Overweight PT 19)

 
February 25, 2021
11:03 ESTAMRN
Amarin to have strong execution year ahead, says Piper Sandler
Piper Sandler analyst Yasmeen Rahimi is confident of Vascepa's path forward in the global market following Amarin's "successful" earnings call, and sees approval in the EU and China later this year, the analyst tells investors in a research note. The analyst also remains bullish on Vascepa's U.S. sales as Amarin makes headway into persistent CV risk patients and expects Phase 3 PREPARE-IT COVID-19 data from Argentina and YE21 for Phase 4 MITIGATE-IT readout from the U.S. in 2021. Rahimi made no change to her Overweight rating or $19 price target.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 3     Views: 0
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board








Financial Market Data provided by
.
Loading...